Knowledge Palette, Inc.

Knowledge Palette, Inc. , based in Kanagawa, Japan, specializes in advanced gene expression analysis technologies to enhance healthcare solutions through data-driven cellular manipulation. Knowledge Palette, Inc. was founded in 2018 and focuses on gene expression analysis to improve healthcare solutions.

The company has received Series B funding of JPY 900 million from Zeon Corporation on July 18, 2023, bringing the total amount raised to JPY 900 million at a current valuation of JPY 5,147. 741 million. The CEO and co-founder, Hiroki Danno, has played a pivotal role in the company’s strategic vision. Knowledge Palette specializes in advanced gene expression analysis technologies aimed at enhancing healthcare solutions through data-driven cellular manipulation.

Their offerings include high-precision transcriptional profiling to analyze large-scale cellular data, which aids in identifying optimal drug compounds and cultivation conditions. They address unmet medical needs in developing cell therapies and regenerative medicine, particularly in regions with a focus on healthcare innovation, such as Japan, the United States, and Europe. Their clientele comprises pharmaceutical companies and research institutions seeking to refine drug development processes and improve cell-based therapies. Knowledge Palette generates revenue through partnerships with pharmaceutical companies and research institutes, focusing on B2B transactions.

These typically involve service agreements for specialized gene expression analysis services aimed at enhancing drug development and quality control. They may explore subscription models for ongoing access to their data analysis platforms, allowing clients to continuously leverage their expertise. Specific pricing plans or flagship products are not disclosed, but their services revolve around high-quality gene expression profiling and cell culture optimization designed for the biotech and pharmaceutical sectors. In July 2023, Knowledge Palette, Inc.

raised JPY 900 million in Series B funding from Zeon Corporation to accelerate technological development and joint research activities. Future growth strategies include designing new products to enhance their gene expression analysis capabilities and expanding into new geographic markets, particularly in Europe and North America, by 2024. The recent funding will support these initiatives to strengthen their market presence and product offerings.